Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 145Breast Neoplasms 113Prostatic Neoplasms 58Multiple Myeloma 57Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 42Ovarian Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 34Leukemia, Lymphocytic, Chronic, B-Cell 33Colorectal Neoplasms 32Carcinoma, Renal Cell 26Recurrence 25Leukemia, Myeloid, Acute 25Urinary Bladder Neoplasms 23Myasthenia Gravis 23Carcinoma, Hepatocellular 23Triple Negative Breast Neoplasms 21Lymphoma, Large B-Cell, Diffuse 21Squamous Cell Carcinoma of Head and Neck 20Small Cell Lung Carcinoma 20Lymphoma, Follicular 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 17Melanoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15

Interventions

pembrolizumab 2X-Rays 2Specimen Handling 2Taxes 1Radiation 1Phantoms, Imaging 1Paclitaxel 1Minimally Invasive Surgical Procedures 1Magnetic Resonance Spectroscopy 1Indocyanine Green 1Congresses as Topic 1Carboplatin 1Brachytherapy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinosarcoma × 90 days × Clear all
NCT04214067 2026-05-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
164 enrolled
Sarcoma

Carcinosarcoma

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT05646316 2026-03-27

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

NRG Oncology

Phase 3 Recruiting
428 enrolled
Sarcoma

Carcinosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡